Form 4: Upstream Bio CBO Granted 25,000 RSUs, 75,000 Options

Upstream Bio's Chief Business Officer, Adam Houghton, received grants of 25,000 restricted stock units and options for 75,000 shares.

Summary

• Adam Houghton, Chief Business Officer of Upstream Bio, Inc. (UPB), was granted 25,000 shares of Common Stock in the form of Restricted Stock Units (RSUs) on January 2, 2026.
• Each RSU represents the contingent right to receive one share of Common Stock upon vesting, with vesting occurring in sixteen equal quarterly installments following January 1, 2026, subject to continued service.
• Additionally, Houghton was granted stock options to purchase 75,000 shares of Common Stock with an exercise price of $27.07 per share on January 2, 2026.
• The shares underlying these options will vest in forty-eight equal monthly installments following January 1, 2026, also subject to continued service.
• The stock options have an expiration date of January 1, 2036.

Sentiment

Score: 7

Explanation: The equity grants to a key executive align management's long-term interests with shareholder value, which is generally viewed positively for corporate governance and retention.

Positives

• Equity grants to the Chief Business Officer align management's long-term interests with those of shareholders, promoting sustained performance.
• The grants serve as a retention mechanism, incentivizing the executive to remain with the company through the vesting periods.

Negatives

• The issuance of new equity, even through grants, can lead to minor dilution for existing shareholders over time as shares vest and options are exercised.

Risks

• Vesting of both RSUs and stock options is contingent upon the reporting person's continued service, meaning the executive must remain employed to realize the full benefit of the grants.

Future Outlook

The vesting schedules for the RSUs and stock options extend several years into the future, indicating an expectation of continued service from the Chief Business Officer and a long-term incentive structure.

Industry Context

Equity compensation, including restricted stock units and stock options, is a standard practice across publicly traded companies, particularly in the biotechnology sector, to attract, retain, and motivate key executives. These grants are designed to align executive performance with shareholder value creation over the long term.

Comparison to Industry Standards

• Equity grants to executives, including RSUs and stock options, are a common form of compensation in the biotechnology industry, aligning executive incentives with long-term shareholder value.
• The size of the grant is typical for a Chief Business Officer at a company of this stage, though specific comparisons would require detailed peer group analysis not provided in this filing.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution from future share issuance, but also benefit from aligned management incentives.
• Employees (specifically the CBO): Enhanced compensation package and long-term incentive to contribute to company growth.

Next Steps

• The Chief Business Officer's continued service is required for the vesting of the granted RSUs and stock options.

Key Dates

Recommendation

The filing details standard equity compensation for a key executive, which generally aligns management's interests with shareholders. It does not provide new information on company performance or strategy that would warrant a change in investment thesis.

Keywords

Upstream Bio, UPB, Adam Houghton, Chief Business Officer, CBO, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Compensation, Insider Transaction, Form 4